
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced […]